FDA Rx-To-OTC Switch Petition Refusal Would Not Result In WellPoint Suit
This article was originally published in The Tan Sheet
Executive Summary
WellPoint Health Networks will not sue FDA if the agency chooses to reject the health insurer's petitions on forcing Rx low- and non-sedating antihistamines to over-the-counter status
You may also be interested in...
FDA’s Crawford Backs Away From Forced Antihistamine Switch Controversy
FDA says it would like to "stimulate" Rx-to-OTC switches where appropriate, but not "force" the policy on drug makers
Pfizer, Aventis Still See Wiggle Room On FDA-Mandated Switches
FDA likely will face a legal challenge regardless of whether the agency decides to implement mandated Rx-to-OTC switches or chooses a more indirect policy yielding similar results, according to comments made by Aventis and Pfizer executives
Schering OTC Claritin Post-Approval Filings To Include Hypospadia Reports
Schering-Plough's post-approval commitments for OTC Claritin include submitting to FDA reported cases of the birth defect hypospadia following maternal ingestion of loratadine, the company said